Chimiothérapie néo-adjuvante par doxorubicine et vinorelbine dans le traitement d’un cancer du sein pendant la grossesse: cas clinique et revue de la littérature

Abstract

Introduction: Little published data is available about chemotherapy in pregnant women, particularly concerning the use of vinorelbine, or the association of vinorelbine and anthracyclines in a neoadjuvant context. The focus of this paper is a case study of a woman in the second trimester of pregnancy who presented with locally advanced breast cancer.Case: A 42-year-old pregnant woman with a T4bN1M0 breast cancer who received neoadjuvant chemotherapy including doxorubicin (60 mg/m 2 ) and vinorelbine (30 mg/m 2 day 1 and 8) every three weeks for four cycles, from the 26 th to the 38 th week of gestation. During the 38 th week of pregnancy the patient spontaneously delivered a male infant whose birthweight and Apgar score were normal. The newborn did not have any anomalies. The patient experienced a clinical improvement with a response rate of 50%. The child showed normal development and growth at 26 months.Discussion: Combined chemotherapy including doxorubicin and vinorelbine should be taken into consideration as neoadjuvant treatment for pregnant women with locally advanced breast cancer.

Breast Cancer in Morocco: A Literature Review

“…Validating and standardizing these predictors should be valuable and helpful for clinicians. Anthracyclines combined with Vinorelbine as neoadjuvant chemotherapy for pregnant patients with locally advanced breast cancer seems to be benefic and non-harmful for fetus (Mrabti et al, 2010).…”